Development and Biological Evaluation of Potent and Selective c-KIT^D816V Inhibitors

Abstract excerpt

The c-KIT tyrosine kinase has emerged as a potential therapeutic target for an array of diseases. However, there exists a drug resistance that is caused by mutations in c-KIT; therefore, c-KIT remains as a clinical challenge due to limited effective treatment options for therapies. For example, the acquired activating point mutation D816V significantly impairs the efficacy of targeted cancer therapies....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Gastrointestinal Tumor Research and Treatment
• Share to Mast cells and histamine
• Share to Monoclonal and Polyclonal Antibodies Research